A community-based collaboration to build prediction models for short-term discontinuation of docetaxel in metastatic castration-resistant prostate cancer
暂无分享,去创建一个
Stephen R. Piccolo | Luke N. Kumar | R. Greiner | Eyal Gofer | L. Elo | G. Stolovitzky | R. Wolfinger | J. Costello | H. Scher | Thea C. Norman | J. Guinney | E. C. Neto | Tao Wang | Fatemeh Seyednasrollah | O. Sartor | Christiane Fuchs | D. Koestler | C. Sweeney | C. Ryan | H. Soule | J. Christopher Bare | Liji Shen | K. Abdallah | R. Vega | Thomas V Yu | F. Zhou | Kimberly Kanigel Winner | L. Shen
[1] Eric Bender,et al. Challenges: Crowdsourced solutions , 2016, Nature.
[2] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.
[3] Ana L. Teixeira,et al. Prediction of human population responses to toxic compounds by a collaborative competition , 2015, Nature Biotechnology.
[4] K. Czene,et al. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Iasonos,et al. Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials , 2015, Oncotarget.
[6] M. Moyad. Docetaxel and Prednisone with or without Lenalidomide in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer ( MAINSAIL ) : A Randomised , Double-Blind , Placebo-Controlled Phase 3 Trial , 2015 .
[7] Yang Xie,et al. A community computational challenge to predict the activity of pairs of compounds , 2014, Nature Biotechnology.
[8] F. Saad,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.
[9] D. Grobbee,et al. Improving clinical trial efficiency by biomarker-guided patient selection , 2014, Trials.
[10] C. Evans,et al. The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions. , 2014, The Canadian journal of urology.
[11] J. Keilwagen,et al. Area under Precision-Recall Curves for Weighted and Unweighted Data , 2014, PloS one.
[12] M. Morris,et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] I. Tannock,et al. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. , 2014, European urology.
[14] I. Tannock,et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[16] Thierry Gil,et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.
[17] M. Gleave,et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J C Costello,et al. Seeking the Wisdom of Crowds Through Challenge‐Based Competitions in Biomedical Research , 2013, Clinical pharmacology and therapeutics.
[19] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[20] Johannes B Reitsma,et al. Beyond diagnostic accuracy: the clinical utility of diagnostic tests. , 2013, Clinical chemistry.
[21] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[22] Diogo M. Camacho,et al. Wisdom of crowds for robust gene network inference , 2012, Nature Methods.
[23] L. Decoster,et al. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution. , 2012, Anticancer research.
[24] P. Albers,et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[26] G. Sonpavde. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer , 2011 .
[27] M. Carducci,et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.
[28] C. Nabhan. Sipuleucel-T immunotherapy for castration-resistant prostate cancer , 2015 .
[29] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[30] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[31] Lior Rokach,et al. Ensemble-based classifiers , 2010, Artificial Intelligence Review.
[32] H. Kalantari. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer , 2009, British Journal of Cancer.
[33] A. Italiano,et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. , 2009, European urology.
[34] J. Machiels,et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] I. Tannock,et al. A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.
[37] Tony O’Hagan. Bayes factors , 2006 .
[38] J. Jett,et al. Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[39] Mark Goadrich,et al. The relationship between Precision-Recall and ROC curves , 2006, ICML.
[40] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[41] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[42] Innovation OR Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .
[43] P. Kantoff,et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Kevin Regan,et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .